AstraZeneca Settles Crestor Patent Case With Actavis

AstraZeneca Plc, the U.K.’s second-biggest drugmaker, agreed to settle a lawsuit against generic manufacturer Actavis Inc. that alleged violation of the patent on the company’s best-selling Crestor cholesterol treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.